Opportunities and Challenges in Developing a Cryptosporidium Controlled Human Infection Model for Testing Antiparasitic Agents
Open Access
- 6 April 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 7 (5) , 959-968
Abstract
Cryptosporidiosis is a leading cause of moderate-to-severe diarrhea in low- and middle-income countries, responsible for high mortality in children younger than two years of age, and it is also strongly associated with childhood malnutrition and growth stunting. There is no vaccine for cryptosporidiosis and existing therapeutic options are suboptimal to prevent morbidity and mortality in young children. Recently, novel therapeutic agents have been discovered through high-throughput phenotypic and target-based screening strategies, repurposing malaria hits, etc., and these agents have a promising preclinical in vitro and in vivo anti-Cryptosporidium efficacy. One key step in bringing safe and effective new therapies to young vulnerable children is the establishment of some prospect of direct benefit before initiating pediatric clinical studies. A Cryptosporidium controlled human infection model (CHIM) in healthy adult volunteers can be a robust clinical proof of concept model for evaluating novel therapeutics. CHIM could potentially accelerate the development path to pediatric studies by establishing the safety of a proposed pediatric dosing regimen and documenting preliminary efficacy in adults. We present, here, perspectives regarding the opportunities and perceived challenges with the Cryptosporidium human challenge model.Keywords
Funding Information
- Novartis
- Wellcome Trust (219639/Z/19/Z)
This publication has 67 references indexed in Scilit:
- Cryptosporidium meleagridis: Infectivity in Healthy Adult VolunteersThe American Journal of Tropical Medicine and Hygiene, 2011
- Prolonged Episodes of Acute Diarrhea Reduce Growth and Increase Risk of Persistent Diarrhea in ChildrenGastroenterology, 2010
- High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trialBMC Infectious Diseases, 2009
- Effect of Nitazoxanide in Diarrhea and Enteritis Caused by Cryptosporidium SpeciesClinical Gastroenterology and Hepatology, 2006
- Nitazoxanide: A New Thiazolide Antiparasitic AgentClinical Infectious Diseases, 2005
- The genome of Cryptosporidium hominisNature, 2004
- Health Sequelae of Human Cryptosporidiosis in Immunocompetent PatientsClinical Infectious Diseases, 2004
- A double-‘blind’ placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in aids patients in MexicoTransactions of the Royal Society of Tropical Medicine and Hygiene, 1998
- A Comparison of Endogenous Development of Three Isolates of Cryptosporidium in Suckling Mice1The Journal of Protozoology, 1986
- The bactericidal, fungicidal and sporicidal properties of hydrogen peroxide and peracetic acidJournal of Applied Bacteriology, 1983